IL127717A - History of useful convulsions in the treatment of amyotrophic lateral sclerosis (ALS) - Google Patents

History of useful convulsions in the treatment of amyotrophic lateral sclerosis (ALS)

Info

Publication number: IL127717A
Authority: IL; Israel
Prior art keywords: compound; formula; hydrogen; als; lateral sclerosis
Prior art date: 1996-06-28

Application number

IL12771797A

Other languages

English (en)

Hebrew (he)

Other versions

IL127717A0 (en

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-28

Filing date

1997-06-24

Publication date

2004-09-27

1997-06-24 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

1999-10-28 Publication of IL127717A0 publication Critical patent/IL127717A0/xx

2004-09-27 Publication of IL127717A publication Critical patent/IL127717A/en

Links

206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 14
239000001961 anticonvulsive agent Substances 0.000 title description 3
230000001773 anti-convulsant effect Effects 0.000 title description 2
229960003965 antiepileptics Drugs 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 23
239000001257 hydrogen Substances 0.000 claims abstract description 12
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
125000000217 alkyl group Chemical group 0.000 claims abstract description 11
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 7
239000001301 oxygen Chemical group 0.000 claims abstract description 7
229910052760 oxygen Chemical group 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 6
-1 methylenedioxy group Chemical group 0.000 claims abstract description 6
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 5
125000002009 alkene group Chemical group 0.000 claims abstract description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
239000004480 active ingredient Substances 0.000 claims abstract 4
150000002431 hydrogen Chemical class 0.000 claims abstract 3
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 16
229960004394 topiramate Drugs 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 2
240000008042 Zea mays Species 0.000 claims 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
235000005822 corn Nutrition 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
230000003042 antagnostic effect Effects 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
206010015037 epilepsy Diseases 0.000 description 5
239000002904 solvent Substances 0.000 description 5
230000000946 synaptic effect Effects 0.000 description 5
206010010904 Convulsion Diseases 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
208000033001 Complex partial seizures Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
206010040703 Simple partial seizures Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000002964 excitative effect Effects 0.000 description 2
201000010901 lateral sclerosis Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
208000005264 motor neuron disease Diseases 0.000 description 2
QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 2
VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000000829 suppository Substances 0.000 description 2
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000037158 Partial Epilepsies Diseases 0.000 description 1
229940122907 Phosphatase inhibitor Drugs 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000036982 action potential Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
238000003287 bathing Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
YUMNNMSNSLHINV-UHFFFAOYSA-N chloro sulfamate Chemical compound NS(=O)(=O)OCl YUMNNMSNSLHINV-UHFFFAOYSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
150000002084 enol ethers Chemical class 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
VVNXEADCOVSAER-UHFFFAOYSA-N lithium sodium Chemical compound [Li].[Na] VVNXEADCOVSAER-UHFFFAOYSA-N 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
210000005215 presynaptic neuron Anatomy 0.000 description 1
210000000063 presynaptic terminal Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical compound OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL12771797A 1996-06-28 1997-06-24 History of useful convulsions in the treatment of amyotrophic lateral sclerosis (ALS) IL127717A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2200696P	1996-06-28	1996-06-28
PCT/US1997/010955 WO1998000131A1 (en)	1996-06-28	1997-06-24	Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (als)

Publications (2)

Publication Number	Publication Date
IL127717A0 IL127717A0 (en)	1999-10-28
IL127717A true IL127717A (en)	2004-09-27

Family

ID=21807346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12771797A IL127717A (en)	1996-06-28	1997-06-24	History of useful convulsions in the treatment of amyotrophic lateral sclerosis (ALS)

Country Status (22)

Country	Link
US (1)	US5753694A (uk)
EP (1)	EP0936908B1 (uk)
JP (1)	JP2000514426A (uk)
AP (1)	AP1167A (uk)
AT (1)	ATE214274T1 (uk)
AU (1)	AU725093B2 (uk)
BR (1)	BR9710993A (uk)
CA (1)	CA2258892C (uk)
CZ (1)	CZ293945B6 (uk)
DE (1)	DE69711067T2 (uk)
DK (1)	DK0936908T3 (uk)
ES (1)	ES2176755T3 (uk)
HU (1)	HUP9904318A3 (uk)
IL (1)	IL127717A (uk)
NO (1)	NO317136B1 (uk)
NZ (1)	NZ333588A (uk)
PT (1)	PT936908E (uk)
SI (1)	SI0936908T1 (uk)
SK (1)	SK284331B6 (uk)
UA (1)	UA46112C2 (uk)
WO (1)	WO1998000131A1 (uk)
ZA (1)	ZA975764B (uk)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5985930A (en) *	1996-11-21	1999-11-16	Pasinetti; Giulio M.	Treatment of neurodegenerative conditions with nimesulide
WO2000061138A1 (en) *	1999-04-08	2000-10-19	Ortho-Mcneil Pharmaceutical, Inc.	Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US7553818B2 (en) *	1999-06-14	2009-06-30	Vivus, Inc.	Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) *	1999-06-14	2008-10-16	Tam Peter Y	Compositions and methods for treating obesity and related disorders
US7056890B2 (en)	1999-06-14	2006-06-06	Vivus, Inc.	Combination therapy for effecting weight loss and treating obesity
WO2000076493A1 (en)	1999-06-14	2000-12-21	Thomas Najarian	Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) *	2006-10-27	2008-05-01	Tam Peter Y	Combination Therapy
US7674776B2 (en)	1999-06-14	2010-03-09	Vivus, Inc.	Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) *	1999-06-14	2010-02-09	Vivus, Inc.	Combination therapy for effecting weight loss and treating obesity
US6191117B1 (en) *	2000-07-10	2001-02-20	Walter E. Kozachuk	Methods of producing weight loss and treatment of obesity
EP1345602B1 (en) *	2000-11-30	2010-07-21	Novodermix International Limited	Wound healing
DE60219961T8 (de) *	2001-02-02	2008-04-17	Ortho-Mcneil Pharmaceutical, Inc.	Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
MXPA04004572A (es) *	2001-11-14	2005-07-05	Ralph Ryback	Metodo para el tratamiento de enfermedades autoinmunes.
AU2003218345A1 (en) *	2002-11-06	2004-06-03	Mount Sinai School Of Medicine	Treatment of amyotrophic lateral sclerosis with nimesulide
US20060041022A1 (en) *	2002-11-06	2006-02-23	Pasinetti Giulio M	Treatment of amyotrophic lateral sclerosis with nimesulide
US20050070524A1 (en) *	2003-06-06	2005-03-31	Pharmacia Corporation	Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
MY147767A (en) *	2004-06-16	2013-01-31	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) *	2004-06-16	2006-08-23	Janssen Pharmaceutica Nv	Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
DE602005008084D1 (de) *	2004-08-24	2008-08-21	Janssen Pharmaceutica Nv	Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
IS7748A (is) *	2005-03-17	2006-09-18	Actavis Group	Samsetning fyrir töflur sem innihalda topiramate
KR20080012360A (ko) *	2005-05-20	2008-02-11	얀센 파마슈티카 엔.브이.	설파미드 유도체의 제조 방법
US20070155823A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) *	2005-12-19	2013-07-30	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) *	2005-12-19	2013-07-23	Janssen Pharmaceutica, N.V.	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) *	2005-12-19	2014-05-06	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) *	2005-12-19	2014-04-08	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en) *	2005-12-19	2015-01-20	Janssen Pharmaceutica Nv	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155824A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070191474A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191460A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191451A1 (en) *	2006-02-15	2007-08-16	Smith-Swintosky Virginia L	Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
EA200870556A1 (ru) *	2006-05-19	2009-06-30	Янссен Фармацевтика Н.В.	Комбинированная терапия в лечении эпилепсии и родственных расстройств
FR2903019A1 (fr) *	2006-06-30	2008-01-04	Univ Claude Bernard Lyon I Eta	Utilisation d'un inhibiteur de l'anhydrase carbonique, pour la preparation d'un medicament destine a traiter des degenerescences du muscle squelettique
US20090247616A1 (en) *	2008-03-26	2009-10-01	Smith-Swintosky Virginia L	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) *	2008-03-26	2009-10-01	Abdel-Magid Ahmed F	Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) *	2008-06-09	2009-12-10	Thomas Najarian	Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en)	2008-06-09	2013-11-12	Vivus, Inc.	Low dose topiramate/phentermine composition and methods of use thereof
EA018567B1 (ru)	2008-06-23	2013-08-30	Янссен Фармацевтика Нв	Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) *	2008-07-22	2014-08-26	Janssen Pharmaceutica Nv	Substituted sulfamide derivatives
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4513006A (en) *	1983-09-26	1985-04-23	Mcneil Lab., Inc.	Anticonvulsant sulfamate derivatives
US4792569A (en) *	1987-08-27	1988-12-20	Mcneilab, Inc.	Anticonvulsant phenethyl sulfamates
US5384327A (en) *	1992-12-22	1995-01-24	Mcneilab, Inc.	Anticonvulsant sorbopyranose sulfamates

1997
- 1997-06-23 US US08/881,023 patent/US5753694A/en not_active Expired - Fee Related
- 1997-06-24 UA UA98126945A patent/UA46112C2/uk unknown
- 1997-06-24 IL IL12771797A patent/IL127717A/en not_active IP Right Cessation
- 1997-06-24 AU AU35010/97A patent/AU725093B2/en not_active Ceased
- 1997-06-24 SK SK1806-98A patent/SK284331B6/sk unknown
- 1997-06-24 PT PT97931367T patent/PT936908E/pt unknown
- 1997-06-24 CZ CZ19984279A patent/CZ293945B6/cs not_active IP Right Cessation
- 1997-06-24 EP EP97931367A patent/EP0936908B1/en not_active Expired - Lifetime
- 1997-06-24 AT AT97931367T patent/ATE214274T1/de not_active IP Right Cessation
- 1997-06-24 HU HU9904318A patent/HUP9904318A3/hu unknown
- 1997-06-24 WO PCT/US1997/010955 patent/WO1998000131A1/en not_active Ceased
- 1997-06-24 ES ES97931367T patent/ES2176755T3/es not_active Expired - Lifetime
- 1997-06-24 CA CA002258892A patent/CA2258892C/en not_active Expired - Fee Related
- 1997-06-24 DK DK97931367T patent/DK0936908T3/da active
- 1997-06-24 BR BR9710993-2A patent/BR9710993A/pt not_active Application Discontinuation
- 1997-06-24 JP JP10504245A patent/JP2000514426A/ja active Pending
- 1997-06-24 DE DE69711067T patent/DE69711067T2/de not_active Expired - Fee Related
- 1997-06-24 AP APAP/P/1998/001428A patent/AP1167A/en active
- 1997-06-24 NZ NZ333588A patent/NZ333588A/xx unknown
- 1997-06-24 SI SI9730259T patent/SI0936908T1/xx unknown
- 1997-06-27 ZA ZA975764A patent/ZA975764B/xx unknown
1998
- 1998-12-22 NO NO19986054A patent/NO317136B1/no unknown

Also Published As

Publication number	Publication date
US5753694A (en)	1998-05-19
HUP9904318A2 (hu)	2000-05-28
DE69711067T2 (de)	2002-09-19
NZ333588A (en)	2000-07-28
UA46112C2 (uk)	2002-05-15
JP2000514426A (ja)	2000-10-31
AU3501097A (en)	1998-01-21
NO317136B1 (no)	2004-08-23
ES2176755T3 (es)	2002-12-01
CA2258892C (en)	2005-08-09
NO986054L (no)	1999-03-01
AP1167A (en)	2003-06-30
EP0936908B1 (en)	2002-03-13
BR9710993A (pt)	2002-02-26
ATE214274T1 (de)	2002-03-15
WO1998000131A1 (en)	1998-01-08
DE69711067D1 (de)	2002-04-18
SK180698A3 (en)	2000-07-11
PT936908E (pt)	2002-08-30
HUP9904318A3 (en)	2001-02-28
AP9801428A0 (en)	1998-12-31
CZ293945B6 (cs)	2004-08-18
CA2258892A1 (en)	1998-01-08
SI0936908T1 (en)	2002-12-31
ZA975764B (en)	1998-12-28
EP0936908A1 (en)	1999-08-25
DK0936908T3 (da)	2002-05-27
IL127717A0 (en)	1999-10-28
AU725093B2 (en)	2000-10-05
CZ427998A3 (cs)	1999-08-11
SK284331B6 (sk)	2005-01-03
NO986054D0 (no)	1998-12-22

Legal Events

Date	Code	Title
2005-02-20	FF	Patent granted
2005-03-20	KB	Patent renewed
2008-02-10	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL127717A (en)	2004-09-27	History of useful convulsions in the treatment of amyotrophic lateral sclerosis (ALS)
Lindsberg et al.	1991	Platelet‐activating factor in stroke and brain injury
Engel et al.	1984	Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)
Beyer et al.	1998	Antioxidant properties of melatonin—an emerging mystery
Meltzer et al.	1979	Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant
EP1414426B1 (en)	2006-03-01	Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
Fujimoto et al.	1999	Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats
Kopf et al.	2001	Glucose plus choline improve passive avoidance behaviour and increase hippocampal acetylcholine release in mice
Rezvani et al.	1997	Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats
Hardeland et al.	2008	Melatonin beyond its classical functions
TW360656B (en)	1999-06-11	Purin-6-one derivatives having cGMP-metabolizing PDEs inhibiting activity, the preparation processes and the pharmaceutical preparation thereof
Labrid et al.	1992	Neurochemical and pharmacological properties of tianeptine, a novel antidepressant
JP2019536788A (ja)	2019-12-19	Ｔ型カルシウムチャンネルブロッカーを含有する薬学的合剤
Onuma et al.	1998	A calcineurin inhibitor, FK506, blocks voltage-gated calcium channel-dependent LTP in the hippocampus
US6350752B1 (en)	2002-02-26	Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
EP0808166A1 (fr)	1997-11-26	Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports
Söderpalm et al.	1999	Naloxone reverses disinhibitory/aggressive behavior in 5, 7-DHT-lesioned rats; involvement of GABAA receptor blockade?
Shuto et al.	1998	Enhancement of serotonergic neural activity contributes to cyclosporine-induced tremors in mice
D'ANDREA et al.	1996	Dual mechanism for cAMP-dependent modulation of Ca2+ signalling in articular chondrocytes
Fontaine et al.	1985	Efficacy and withdrawal of two potent benzodiazepines: bromazepam and lorazepam
Kolbasa et al.	1991	Effect of chronic treatment on the cardiovascular and behavioral responses of 8-OH-DPAT in conscious normotensive rats
Weiss et al.	1985	Adenosine antagonists: lack of effect on the inhibition of kindled seizures in rats by carbamazepine
Rudolf et al.	1989	Electrooculographic study in the chicken after treatment with neurotoxin 6-hydroxydopamine
AU653966B2 (en)	1994-10-20	An imidazobenzodiazepine for the treatment of sleep disorders
KR20050108402A (ko)	2005-11-16	만성 피부 질환의 치료제 및/또는 예방제